Abstract Details
|
Valentina Emmanuele, MD, PhD
(NYP at CUIMC)
PRESENTER |
Dr. Emmanuele has nothing to disclose. |
| No disclosure on file | |
| No disclosure on file | |
| Richard H. Haas, MD | Dr. Haas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SPARC. Dr. Haas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Haas has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various Law Firms. Dr. Haas has stock in Various Companies Stock Trading. The institution of Dr. Haas has received research support from NIH North American Mitochondrial Disease Consortium. The institution of Dr. Haas has received research support from Reneo Pharma. The institution of Dr. Haas has received research support from Astellas Pharma. The institution of Dr. Haas has received research support from Acadia Pharma. The institution of Dr. Haas has received research support from Taysha Gene Therapies. The institution of Dr. Haas has received research support from Tisento Pharma. |
| No disclosure on file | |
| Douglas A. Kerr, MD, PhD | Dr. Kerr has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Trace Neuroscience. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Spolia Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for AAVantgarde Therrapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Trace Neuroscience. Dr. Kerr has or had stock in Dyne Therapeutics. |
| Russell P. Saneto, DO, PhD (Seattle Childrens Hospital) | Dr. Saneto has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for REATA. Dr. Saneto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW Pharmaceuticals. The institution of Dr. Saneto has received research support from NIH. The institution of Dr. Saneto has received research support from Zogenix. The institution of Dr. Saneto has received research support from GW Pharmaceuticals. |
| Bruce H. Cohen, MD, FAAN (Akron Children's Hospital) | Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abliva/NeuroVive/Pharming. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Modis/Zogenix/USB. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision BioSciences . Dr. Cohen has received personal compensation in the range of $0-$499 for serving as a Consultant for Pretzel. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stealth Bio. Dr. Cohen has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Allergan. The institution of Dr. Cohen has received research support from Stealth Biotherapeutics. The institution of Dr. Cohen has received research support from BioElectron Technologies/PTC. The institution of Dr. Cohen has received research support from Astellas/MitoBridge. The institution of Dr. Cohen has received research support from Reneo Pharmaceuticals. The institution of Dr. Cohen has received research support from Abliva/Pharming. The institution of Dr. Cohen has received research support from Tisento. Dr. Cohen has received publishing royalties from a publication relating to health care. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant with US DOJ/HHS; DVIC. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a CPT Advisor with AAN. Dr. Cohen has a non-compensated relationship as a Officer with Child Neurology Society that is relevant to AAN interests or activities. Dr. Cohen has a non-compensated relationship as a Officer with Child Neurology Foundation that is relevant to AAN interests or activities. |
| Johan Van Hove | The institution of Johan Van Hove has received research support from CureARS, NIH, NKH Crusaders, Mito Foundation, Brodyn's Friends, Les Petits Bourdons, Maud & Vic NKH fund, Tucker's Titans, Mikaere foundation. Johan Van Hove has received intellectual property interests from a discovery or technology relating to health care. |
| Fernando Scaglia, MD | Dr. Scaglia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. |
| Xiomara Q. Rosales, MD (Columbia University Medical Center-Neuromuscular Division) | No disclosure on file |
| Emanuele Barca, MD, PhD (Columbia University) | Dr. Barca has nothing to disclose. |
| Richard Buchsbaum | No disclosure on file |
| John L. Thompson, PhD (Columbia Univ School of Public Health) | The institution of Dr. Thompson has received research support from NIH. |
| Salvatore DiMauro, MD (Columbia University Medical Center) | No disclosure on file |
| Michio Hirano, MD, FAAN (Columbia University Medical Center) | Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Biopharma SRL. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision Biosciences. Dr. Hirano has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Biopharma SRL. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apollo Communication. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Envision Communications. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for 好色先生. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Cure SMA. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Muscular Dystrophy Association. The institution of Dr. Hirano has received research support from UCB. The institution of Dr. Hirano has received research support from Cyclerion. The institution of Dr. Hirano has received research support from Astellas. The institution of Dr. Hirano has received research support from Tisento Therapeutics. The institution of Dr. Hirano has received research support from Stealth Biotherapeutics. The institution of Dr. Hirano has received research support from Abliva. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received personal compensation in the range of $0-$499 for serving as a Study Section Reviewer with NIH. Dr. Hirano has a non-compensated relationship as a Research Advisory Board member with Muscular Dystrophy Association that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific and Medical Advisory Board member with United Mitochondrial Disease Foundation that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific Advisory Board member with Barth Syndrome Foundation that is relevant to AAN interests or activities. |
| No disclosure on file |